Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation
Phase 1/Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Graft Versus Host Disease
Both
Graft Versus Host Disease
Trial Information
Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation
Inclusion Criteria:
1. Patients undergoing allogeneic stem cell transplantation.
2. No previous history of psychosis. -
Exclusion Criteria:
1. Previous history of psychosis.
2. Consumption of cannabis during the last 2 moths before transplantation. -
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
Overall percentage of patients with acute GVHD at day 100 post-transplant
Outcome Time Frame:
day 100
Safety Issue:
Yes
Principal Investigator
Moshe Yeshurun, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Davidoff cancer center, Beilinson hospital, Rabin Medical Center
Authority:
Israel: Ethics Commission
Study ID:
6276
NCT ID:
NCT01385124
Start Date:
September 2012
Completion Date:
April 2015
Related Keywords:
- Graft Versus Host Disease
- Cannabidiol
- GVHD
- Allogeneic transplantation
- Prophylaxis
- Graft vs Host Disease
Name | Location |
|---|
